By SplitShire. CC0 Creative Commons.

Mexico’s presidential elections continue dominating local airwaves. But with little word on healthcare policy, the sector continues its calls for clear proposals from candidates. Funsalud’s Executive President urged candidates to present their health proposals. The Mexican Center of Economic and Budget Research informed that providing universal healthcare for Mexico, a stated objective of all candidates, would cost MX$915 million.

Bayer’s acquisition of Monsanto remains in the spotlight. In Mexico, Bayer will be forced to sell its genetically modified businesses before the acquisition. Gilead expands its HIV line and Merck’s drug for lung cancer shows positive results. Researchers reported an increase in mortality risk caused by workplace stress in men with previous cardiovascular diseases.

Mexico Health Review spoke with Novo Nordisk’s Yiannis Mallis on the company’s plans to fight obesity and diabetes

Now, jump into last week’s highlights:



With the presidential elections looming closer, Funsalud’s Executive President, Hector Valles, called for candidates to present clear policies to address healthcare.

The Mexican Center of Economic and Budget Research estimated that covering the entire Mexican population for 13 key diseases would cost MX$915 billion. The diseases included would be HIV, hypertension, diabetes and depression among many other.

Farmacias Guadalajara allies with BBVA Bancomer to allow clients to pay through BBVA Wallet or through Sticker Wallet.

Bayer closes deal to buy Monsanto for US$63 billion and plans to retire Monsanto’s name. Mexico’s Federal Commission of Economic Competition (COFECE) conditioned the merger in the country to the sale of its genetically modified seed and cotton business.



Gilead partners with immunotherapy company Hookipa Biotech to expand its HIV and Hepatitis B drug portfolio.

In an effort to cut drug prices, the FDA looks toward speeding up the approval times for rival drugs and shorten drug monopolies. Pharmaceutical companies have not welcomed the idea.

Merck’s Keytruda, for the treatment of newly diagnosed squamous lung cancer, has proven to improve survival as a standalone medication.

Tagged with →  
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *